Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.”
Email: jackfriday2011(at)hotmail.co.uk
Thursday, March 12, 2009
Gilead outbid Astellas for CV
Gilead Sciences is to buy CV Therapeutics for $1.4 billion, or $20 per share. The move deals a blow to Astellas's efforts to buy CV, which the Japanese company had been courting for $1 billion, or $16 per share, since November.
No comments:
Post a Comment